Anthropic’s New AI Model Could Supercharge CrowdStrike’s Growth
Wolfe Research upgrades CrowdStrike to Outperform and sets a $450 price target.
Already have an account? Sign in.
Wolfe Research upgrades CrowdStrike to Outperform and sets a $450 price target.
Wells Fargo says Boston Scientific’s CHAMPION-AF trial met all endpoints for WATCHMAN FLX but calls results “good, not great” due to slightly higher stroke rate vs blood thinners.
Morgan Stanley upgrades Insmed to Overweight and raises price target to $212.
Aurinia Pharmaceuticals has agreed to acquire Kezar Life Sciences for $6.955 in cash per share plus a Contingent Value Right (CVR).